predictNMB (Q68918): Difference between revisions

From MaRDI portal
Importer (talk | contribs)
Removed claim: imports (P585): magrittr (Q31150)
Added link to MaRDI item.
 
(6 intermediate revisions by one other user not shown)
Property / last update
19 May 2023
Timestamp+2023-05-19T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
 
Property / last update: 19 May 2023 / rank
Normal rank
 
Property / imports
 
Property / imports: rlang / rank
Normal rank
 
Property / imports
 
Property / imports: tibble / rank
Normal rank
 
Property / imports
 
Property / imports: tidyr / rank
Normal rank
 
Property / cites work
 
Property / cites work: predictNMB: An R package to estimate if or when a clinical prediction model is worthwhile / rank
Normal rank
 
Property / software version identifier
 
0.2.1
Property / software version identifier: 0.2.1 / rank
 
Normal rank
Property / software version identifier: 0.2.1 / qualifier
 
publication date: 3 June 2023
Timestamp+2023-06-03T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
Property / last update
 
3 June 2023
Timestamp+2023-06-03T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
Property / last update: 3 June 2023 / rank
 
Normal rank
Property / description
 
Estimates when and where a model-guided treatment strategy may outperform a treat-all or treat-none approach by Monte Carlo simulation and evaluation of the Net Monetary Benefit. Details can be viewed in Parsons et al. (2023) <doi:10.21105/joss.05328>.
Property / description: Estimates when and where a model-guided treatment strategy may outperform a treat-all or treat-none approach by Monte Carlo simulation and evaluation of the Net Monetary Benefit. Details can be viewed in Parsons et al. (2023) <doi:10.21105/joss.05328>. / rank
 
Normal rank
Property / author
 
Property / author: Rex Parsons / rank
 
Normal rank
Property / author
 
Property / author: Robin Blythe / rank
 
Normal rank
Property / author
 
Property / author: Adrian G. Barnett / rank
 
Normal rank
Property / copyright license
 
Property / copyright license: GNU General Public License / rank
 
Normal rank
Property / copyright license: GNU General Public License / qualifier
 
edition/version: ≥ 3 (English)
Property / depends on software
 
Property / depends on software: R / rank
 
Normal rank
Property / depends on software: R / qualifier
 
Property / imports
 
Property / imports: assertthat / rank
 
Normal rank
Property / imports
 
Property / imports: cutpointr / rank
 
Normal rank
Property / imports
 
Property / imports: dplyr / rank
 
Normal rank
Property / imports
 
Property / imports: ggplot2 / rank
 
Normal rank
Property / imports
 
Property / imports: magrittr / rank
 
Normal rank
Property / imports
 
Property / imports: pmsampsize / rank
 
Normal rank
Property / imports
 
Property / imports: rlang / rank
 
Normal rank
Property / imports
 
Property / imports: scales / rank
 
Normal rank
Property / imports
 
Property / imports: stats / rank
 
Normal rank
Property / imports
 
Property / imports: tibble / rank
 
Normal rank
Property / imports
 
Property / imports: tidyr / rank
 
Normal rank
Property / cites work
 
Property / cites work: predictNMB: An R package to estimate if or when a clinical prediction model is worthwhile / rank
 
Normal rank
Property / MaRDI profile type
 
Property / MaRDI profile type: MaRDI software profile / rank
 
Normal rank
links / mardi / namelinks / mardi / name
 

Latest revision as of 19:56, 12 March 2024

Evaluate Clinical Prediction Models by Net Monetary Benefit
Language Label Description Also known as
English
predictNMB
Evaluate Clinical Prediction Models by Net Monetary Benefit

    Statements

    0 references
    0.1.0
    12 April 2023
    0 references
    0.2.0
    19 May 2023
    0 references
    0.2.1
    3 June 2023
    0 references
    0 references
    0 references
    0 references
    3 June 2023
    0 references
    Estimates when and where a model-guided treatment strategy may outperform a treat-all or treat-none approach by Monte Carlo simulation and evaluation of the Net Monetary Benefit. Details can be viewed in Parsons et al. (2023) <doi:10.21105/joss.05328>.
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references